37 results about "Schistosoma Japonicum Infection" patented technology

The invention discloses a recombinant expression carrier containing a schistosoma japonicum gene which is a schistosoma japonicum heat shock protein 60 gene. The invention also discloses a preparation method of the schistosoma japonicum heat shock protein 60 and the application of the recombinant expression carrier. The recombinant expression carrier containing the schistosoma japonicum gene can highly express the schistosoma japonicum heat shock protein 60 gene, and the highly expressed recombinant schistosoma japonicum Hsp60 protein can induce mouse to generate the protection function of resisting the infection of schistosoma japonicum at a certain level.

The invention discloses a method for treating mesenchymal stem cells used for the treatment of Schistosoma japonicum infection. Add IFN-γ and LPS to the culture medium of MSCs, culture at 37°C for 24 hours, and the final concentration of IFN-γ is 5-100ng / ml , the final concentration of LPS is 10-100ng / ml, the stimulating factors are removed, and it is used for treatment after sufficient washing. Its advantages are mainly manifested in the following aspects: 1. Compared with the current treatment mainly targeting parasites, optimized induced MSCs can be used for the treatment of liver fibrosis in infected patients without obvious side effects; 2. Compared with uninduced MSCs , after optimized induction, MSC can significantly reduce liver fibrosis caused by schistosomiasis infection by significantly promoting Th1 response, and obtain better curative effect.

The invention discloses a urine biological marker for early diagnosis of schistosomiasis japonica, wherein the urine biological marker is one or more of xanthonic acid, naphthalenesulfonic acid or heptanoylcarnitine. The sensitivity and specificity of the markers were all greater than 0.9, and the area under the curve (AUC) was greater than 0.9, indicating that the three indicators had good predictive performance and could be used for early diagnosis of schistosomiasis japonica. The invention also discloses a screening method for early diagnosis of schistosomiasis japonica urine biomarkers based on metabolomics. By constructing a mouse schistosomiasis japonica model, the ultra-high performance liquid chromatography-tandem mass spectrometry technology is used to metabolize mouse urine. The omics analysis found and analyzed the characteristic differential metabolites between normal mice and Schistosoma japonicum-infected mice, which were biomarkers for early diagnosis of Schistosomiasis japonicum. The screening method has the characteristics of non-invasiveness, convenience and quickness, and can accurately reflect the difference of the metabolic profile between the mice infected with schistosomiasis japonicum and the normal mice, and has high specificity.

The invention belongs to the field of immunology, and particularly relates to an application of proteantigen molecules from schistosomes such as Japanese schistosome shock proteins 60KDa (SjHSP60), which is the application of Japanese schistosome shock proteins 60KDa for preparing a diagnostic reagent for monitoring comprehensive hepatic pathology injury degree of a schistosomiasis patient. The SjHSP60IgG in blood serum of a Japanese schistosome infected host and subtype IgG1 antibody level thereof are positively correlated to liver granuloma and fibrosis degree, which promotes that the SjHSP60IgG in blood serum and the subtype IgG1 antibody level thereof can be used as an index of evaluating the pathological degree of the liver of the schistosomiasis patient and has potential clinical application value. In the future, the novel diagnostic reagent may be used for monitoring the pathological degree of the liver of the schistosomiasis patient.

The invention provides microRNA and its application in preparation of anti-Schistosoma japonicum infection preparation. Specifically, the present invention provides nucleic acid inhibitory molecules, especially microRNA nucleic acid molecules, which have significant killing or inhibiting effects on Schistosoma japonicum. Experiments show that the specific amiRNA of the present invention has a high ability to kill or inhibit Schistosoma japonicum (especially early stage schistosomiasis). The invention also provides the preparation method, pharmaceutical composition and application of the nucleic acid inhibitory molecule.